ArticleNanomedicine : nanotechnology, biology, and medicine2021
Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Nanofluidic-based electrochemical pump for remotely controlled, on-demand drug delivery.Lab on a chip · 2026Article
- Application Prospects of Nanotechnology in the Diagnosis and Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2026Review
- Smart closed-loop drug delivery systems.Nature reviews bioengineering · 2025Article
- A Comprehensive Review on Nanoparticles as Drug Delivery System and Their Role for Management of Hypertension.Current pharmaceutical biotechnology · 2025Review
- In Vivo Evaluation of Self-assembled nano-Saikosaponin-a for Epilepsy Treatment.Molecular biotechnology · 2024Article
- A Revolutionary Blueprint for Mitigation of Hypertension via Nanoemulsion.BioMed research international · 2022Review
- Emerging nanotechnologies in cardiovascular medicine.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Hypertension is a chronic condition that requires lifelong therapeutic management. Strict adherence to drug administration timing improves efficacy, while poor adherence leads to safety concerns. In light of these challenges, we present a nanofluidic technology that enables long-acting drug delivery with tunable timing of drug administration using buried gate electrodes in nanochannels. We developed a poly(ethylene glycol) methyl ether-block-poly(ε-caprolactone) (PEG-PCL)-based micellar formulation of amlodipine besylate, a calcium channel blocker for hypertension treatment. The electrostatically charged PEG-PCL micellar formulation enhanced drug solubility and rendered amlodipine responsive to electrostatic release gating in nanochannels for sustained release at clinically relevant therapeutic dose. Using a low-power (<3 VDC) gating potential, we demonstrated tunable release of amlodipine-loaded micelles. Additionally, we showed that the released drug maintained biological activity via calcium ion blockade in vitro. This study represents a proof of concept for the potential applicability of our strategy for chronotherapeutic management of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.